Human Gut Mycobiota Tune Immunity via CARD9-Dependent Induction of Anti-fungal IgG Antibodies

Using a multi-kingdom antibody profiling approach, researchers explored the human antibody repertoires against gut commensal fungi.
[Cell]
[zotpress userid=’6445218′ items=’7MD77HYJ’ style=’apa’ cite=’yes’]
AbstractGraphical Abstract
Bookmark

No account yet? Register

Share

Turn Therapeutics Announces First Subjects Enrolled in Human Clinical Trial for the Treatment and Prevention of COVID-19

Turn Therapeutics, Inc. announced enrollment of the first subjects in its COVID-19 treatment and prevention clinical trial. Turn’s flagship product, Hexagen, will be administered intranasally and studied as a method for reducing viral load, as well as uptake, at the critical infection points that line the nasal passage.
[Turn Therapeutics, Inc. (BusinessWire, Inc)]
[zotpress userid=’6445218′ items=’nan’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

COVAXX’s COVID-19 Vaccine, UB-612, Induced Neutralizing Antibodies in 100% of Participants during Phase I Clinical Trial

COVAXX announced positive interim Phase I data from its open-label COVID-19 clinical trial conducted in Taiwan. This study, which evaluated the safety, tolerability, and immunogenicity of UB-612, showed that the vaccine was generally well-tolerated and elicited robust antibody responses comparable to those seen in human convalescent sera.
[COVAXX (BusinessWire, Inc)]
[zotpress userid=’6445218′ items=’nan’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

The Intestinal Neuro-Immune Axis: Crosstalk between Neurons, Immune Cells, and Microbes

The authors summarize recent studies investigating the crosstalk between gut-innervating neurons, resident immune cells, and epithelial cells at homeostasis and during infection, food allergy, and inflammatory bowel disease.
[Mucosal Immunology]
[zotpress userid=’6445218′ items=’V3BUBEN9′ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

A Diagnostic Host Response Biosignature for COVID-19 from RNA Profiling of Nasal Swabs and Blood

A muted immune response was observed in COVID-19 relative to other infections with paradoxical down-regulation of several key differentially expressed genes.
[Science Advances]
[zotpress userid=’6445218′ items=’YTZJGINQ’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

CARD8 Is an Inflammasome Sensor for HIV-1 Protease Activity

Scientists report that the CARD8 inflammasome sensed HIV-1 protease activity. HIV-1 could evade CARD8 sensing because its protease remained inactive in infected cells prior to viral budding.
[Science]
[zotpress userid=’6445218′ items=’G8ES9ACF’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Outcome of SARS-CoV-2 Infection Is Linked to MAIT Cell Activation and Cytotoxicity

Researchers studied the immune cell landscape, with emphasis on mucosal-associated invariant T (MAIT) cells, in cohorts totaling 208 patients with various stages of disease.
[Nature Immunology]
[zotpress userid=’6445218′ items=’B69CJ57W’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Host Immunity Modulates the Efficacy of Microbiota Transplantation for Treatment of Clostridioides difficile Infection

Scientists demonstrated a critical role for the immune system in supporting fecal microbiota transplantation using a murine C. difficile infection system.
[Nature Communications]
[zotpress userid=’6445218′ items=’P627LVYV’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

SARS-CoV-2 ORF9b Inhibits RIG-I-MAVS Antiviral Signaling by Interrupting K63-Linked Ubiquitination of NEMO

The authors report the activation and repression of innate immune response by SARS-CoV-2. They showed that SARS-CoV-2 RNA activated the RIG-I-MAVS-dependent interferon signaling pathway.
[Cell Reports]
[zotpress userid=’1254621′ items=’W4EU5G3B’ style=’apa’ cite=’yes’]
Full ArticleGraphical Abstract
Bookmark

No account yet? Register

Share

Revelation Biosciences Inc. Completes Dosing of Five Single Dose Cohorts and Receives Approval to Initiate a Multiple Dose Cohort to Phase I Clinical Study of REVTx-99, an Experimental Treatment for Respiratory Viral Infection, Including COVID-19

Revelation Biosciences, Inc. announced that it has been granted approval by the Bellberry Human Research Ethics Committee in Australia to add a multiple dose cohort to its Phase I clinical study of REVTx-99 in healthy volunteers. REVTx-99 is in development for the treatment and prevention of respiratory viral infection, including SARS-CoV-2 Infection.
[Revelation Biosciences, Inc. (BusinessWire, Inc)]
[zotpress userid=’6445218′ items=’nan’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

Abzena Selected by Immunome to Develop and Manufacture Antibody Cocktail for Immunome’s COVID-19 Antibody Based Treatment

Immunome, Inc. announced that Abzena was selected as Immunome’s partner research organization for IMM-BCP-01, an investigational therapeutic antibody cocktail for the treatment of COVID-19 being developed to target multiple SARS-CoV-2 antigens.
[Immunome, Inc. (BusinessWire, Inc)]
[zotpress userid=’6445218′ items=’nan’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share
Share